Apr 15, 2024

Long-Term Response to Rituximab vs Tacrolimus in Children with Steroid-Dependent Nephrotic Syndrome

EARNed Credits

0.5

AMA PRA Category 1 CreditTM

CPE Contact Hour

CNE Contact Hour

iStock-1367631371

Chronic Kidney Disease

The need for consistent updates and agile content is imperative for today’s clinician to remain current on the continuum of scientific data. In no therapeutic area is this more essential than in “Cardiometabolic Medicine,” a new term meant to encompass the interconnected and debilitating diagnoses of diabetes mellitus, heart failure, coronary artery disease/acute coronary syndrome, progressive renal insufficiency, and related disorders such as hypertension, hyperlipidemia, and hyperkalemia.  These areas are subject to frequent pivotal trial publications, guidelines updates, FDA action, and outcomes assessments.

Who Should Attend

Primary care physicians, internists, family medicine physicians, allied healthcare professionals and other healthcare providers.

Provided By

course faculty

Melvin Chan MD
Pediatric Nephrology Fellow; Children's Hospital of Colorado

Your only source for ACCREDITED SoMe-delivered serialized professional cardiometabolic education.

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Melvin
Chan

Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC; Patrick Hayes and Nicole McMenamin hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM.

AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours.

AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of continuing pharmacy education credit.

Learners should only claim credit commensurate with the extent of their participation.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME does not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

  1. Read the accreditation information and faculty disclosures at the beginning of this activity.
  2. Read or Review the activity content.
  3. Complete the Post-Activity Test Questions and Evaluation.
  4. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact [email protected].

Apr 15, 2024

Long-Term Response to Rituximab vs Tacrolimus in Children with Steroid-Dependent Nephrotic Syndrome

Related Tweetorial Courses

CKD
Human Nephrogenesis in Preterm Infants
CKD
Albuminuria: The Canary in the Coal Mine of Kidney and Cardiorenal Disease
CKD
The Conundrum of Alkali Therapy in Calcium Phosphate Stone Formers